Development of a Tool to Predict Risk of Behavioral Health Evacuation From Combat.

In the present study, we examined administrative data on 667,437 deployments of at least 30 days duration to Iraq and Afghanistan from 2011 through the end of 2016 to determine risk factors for evacuation from the combat zone for behavioral health reasons. Demographic data, military-specific data, responses on predeployment mental health assessments, and presence of previous treatment for psychiatric conditions were entered into a logistic regression based on expert determination, distinguishing the 2,133 behavioral health evacuations from those deployments that either did not end in evacuation or included evacuations for reasons other than behavioral health. The model, derived from a random half of the sample (training set), was verified on the other half (validation set). Predictor variables used in the model were calendar year; gender; age; rank; marital status; parental status; number of prior war zone deployments; branch of service; screens for symptoms of posttraumatic stress disorder, depression, and hazardous alcohol use on the predeployment mental health assessment; and prior substance- and non-substance-related behavioral health diagnoses. Odds ratios (range: 1.05-3.85) for selected variables that contributed to the model were used to assign risk scores in the Behavioral Health Evacuation Risk Tool, which can aid predicting which service members are more likely to be evacuated from combat for behavioral health reasons, thus indicating where resources can be allocated for behavioral health referrals and war zone care.

Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial.

BACKGROUND: Approximately one-third of patients undergoing interferon-α (IFN-α) therapy for treatment of the hepatitis C virus (HCV) develop major depression, which decreases functioning and may lead to the reduction or discontinuation of treatment. OBJECTIVE: The authors examined the efficacy of citalopram in preventing IFN-α-induced depression in HCV patients. METHOD: This was a randomized, controlled trial comparing citalopram with placebo in 39 HCV patients. RESULTS: The rate of IFN-α-induced depression in the sample was 15.4% (6/39). Randomization to citalopram did not decrease the statistical likelihood of developing IFN-α-induced depression (10.5% for citalopram vs. 20.0% for placebo). CONCLUSION: Citalopram does not prevent depression onset; however, an empirically-supported treatment recommendation for IFN-α-induced depression includes monitoring depressive symptoms throughout antiviral therapy and initiating psychiatric treatment at the initial signs of depression.

Outpatient treatment engagement and abstinence rates following inpatient opioid detoxification.

Many patients with chronic opioid dependence are referred to drug-free outpatient treatment following inpatient detoxification even though successful outpatient treatment engagement and abstinence from opioids occur only in a minority of cases. This retrospective cohort analysis of medical records documents the post-discharge outcome in a treatment setting that maximizes the support during transition to abstinence-oriented outpatient care, with comprehensive social, medical and mental health services, including the availability of naltrexone. Participants were male veterans (N = 112) admitted at an urban VA medical center. Most patients (78%) successfully completed acute detoxification, 49% initiated naltrexone, and 76% accepted a VA aftercare plan. At 90-day follow-up, only 22% remained in aftercare, and < 3% had toxicology-verified abstinence from opioids. At one-year follow-up, 1 out of 5 had been readmitted for detoxification and 4.5% had died. Most patients successfully detoxified from opioids, but very few remained engaged and stabilized in abstinence-oriented outpatient treatment.

Cost effectiveness of testing strategies for chronic hepatitis C.

OBJECTIVE: This paper compares nine strategies for determining hepatitis C antibody and viral status. They combine two tests for antibodies (enzyme immunoassays (EIA), recombinant immunoblot assays (RIBA)) and one for viremia (reverse transcription polymerase chain reaction (PCR)). Using optical density to divide EIA results into three categories (high positive, low positive, negative) was also considered. METHODS: Decision analysis compared strategies on cost as well as sensitivity and specificity with regard to antibody and viral status. Parameters in the decision tree included antibody prevalence, proportion viremic, sensitivity, specificity, and cost of individual tests. RESULTS: The two best strategies are EIA followed by PCR (EIA-->PCR); and EIA with three levels of optical density (EIA-OD), followed by RIBA for EIA-OD low positives, and then PCR for all positives (EIA-OD-->RIBA-->PCR). EIA-->PCR has equal viral sensitivity, slightly lower cost, slightly higher antibody sensitivity, but lower antibody specificity compared to EIA-OD-->RIBA-->PCR. The cost per false antibody positive avoided using EIA-OD-->RIBA-->PCR rather than EIA-->PCR is $36 when prevalence is 5%, and $193 when prevalence is 50%. Using EIA-OD-->RIBA-->PCR rather than EIA-->PCR results in 112 false antibody positives avoided for every true antibody positive missed when prevalence is 5%; this ratio is 18:1 when prevalence is 25%; and 6:1 when prevalence is 50%. CONCLUSIONS: EIA-OD-->RIBA-->PCR is the best choice when prevalence in the tested group is below 20%. As prevalence increases, the choice of EIA-OD-->RIBA-->PCR versus EIA-->PCR will depend on the relative importance of avoiding false antibody positives versus missing true antibody positives. Our analysis makes explicit the magnitude of this trade-off.